Claims for Patent: 5,659,061

Summary for Patent: 5,659,061

Title:	Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
Abstract:	The composition, synthesis, and applications of tumor associated protease activated prodrugs of phosphoramide mustard, isophosphoramide mustard and analogs with detoxification functionalities are described. These drugs release a cytotoxic phosphoramide mustard analog following activation by tumor associated proteases and esterases. The general structure for these drugs is: ##STR1## Wherein R1 is a beta-X-ethyl-amino group which may optionally bear substituents on the nitrogen or carbon atoms; wherein X is a good leaving group such as a halogen; R2 is a beta-X-ethyl-amino group which may optionally bear substituents on the nitrogen or carbon atoms; or an amino group (NH.sub.2) which may optionally be substituted. Wherein A is a benzyloxy derivative with one or more acyloxy or acylamino groups in para or ortho portions relative to the phosphoester; and wherein the acyloxy or acylamino groups are not (substituted or unsubstituted) p-guanidino-benzoyloxy groups or p-guanidino-benzoylamino groups.
Inventor(s):	Glazier; Arnold (Newton, MA)
Assignee:	Drug Innovation & Design, Inc. (Newton, MA)
Application Number:	08/425,477
Patent Claims:	1. An antineoplastic compound represented by the following structural formula: ##STR20## wherein: R1 is a beta-X-ethyl amino group or a beta-X-ethyl amino group substituted on one or more nitrogen or carbon atoms; X is a good leaving group or a halogen; R2 is selected from the group consisting of a beta-X-ethyl amino group, a beta-X-ethyl amino group substituted on one or more nitrogen or carbon atoms, an amino group and a substituted amino group; and A is a benzyloxy derivative with one or more acyloxy or acylamino groups in the para or ortho positions relative to the phosphoester, with the proviso that the acyloxy or acylamino groups are not a substituted or unsubstituted p-guanidino-benzoyloxy group or a p-guanidino-benzoylamino group. 2. An antineoplastic compound of claim 1 of the following structure: ##STR21## Wherein R3 and R4 is H; an alkyl group; a methyl group; or an ethyl group; --CH.sub.2 --CO.sub.2 --Y; or an N substituted methylene-carbonyl-amino group; wherein Y is an alkyl group; a methyl group; or an ethyl group; and R5 is an acyl-oxy group; or an acyl-amino group; and wherein the benzyl ring may optionally be substituted with inert groups; alkyl group; alkyloxy groups, methoxy, or halogens. 3. An antineoplastic compound of claim 2 of the following structure: ##STR22## 4. An antineoplastic compound of claim 3 of the following structure: ##STR23## 5. An antineoplastic compound of claim 4 wherein R5 has the following structure: ##STR24## wherein R6 is a substituted or unsubstituted alkyl or phenyl group; or wherein R6 selected such that R6--COOH is a substituted or unsubstituted amino acid or an oligopeptide comprised of from 2 to about 20 substituted or unsubstituted amino acids. 6. An antineoplastic compound of claim 2 wherein R5 has the following structure: ##STR25## wherein R6 is a substituted or unsubstituted alkyl or phenyl group; or wherein R6 selected such that R6--COOH is a substituted or unsubstituted amino acid or an oligopeptide comprised of from 2 to about 20 substituted or unsubstituted amino acids. 7. An antineoplastic compound of claim 6 wherein: R1 is a beta-X-ethyl-amino group which bears a masked nucleophile substituent on the nitrogen or carbon atoms such that the substituent is located 3, 4, or 5 atoms from the group X; wherein X is a good leaving group or a halogen; and wherein the nucleophile is a hydroxy group; an amino group; a carboxylate group; or a thiol. 8. An antineoplastic compound of claim 2 wherein R5 has the following structure: ##STR26## wherein R6 is a substituted or unsubstituted alkyl or phenyl group; or wherein R6 selected such that R6--COOH is a substituted or unsubstituted amino acid or an oligopeptide comprised of from 2 to about 20 substituted or unsubstituted amino acids; R1 is a beta-X-ethyl-amino group which bears a masked nucleophile substituent on the nitrogen or carbon atoms such that the substituent is located 3, 4, or 5 atoms from the group X; wherein X is a good leaving group or a halogen. 9. An antineoplastic compound of claim 8 of the following structures: ##STR27## wherein R7 is O, NH, or S and R8 is an alkyl group, a substituted or unsubstituted phenyl group, or wherein R8--CO.sub.2 H is a substituted or unsubstituted amino acid. 10. An antineoplastic compound of claim 1 wherein: R1 is a beta-X-ethyl-amino group which bears a masked nucleophile substituent on the nitrogen or carbon atoms such that the substituent is located 3, 4, or 5 atoms from the group X; wherein X is a good leaving group or a halogen. 11. An antineoplastic compound of claim 10 wherein: R2 is a beta-X-ethyl-amino group which may optionally bear substituents on the nitrogen or carbon atoms such that a masked nucleophile is located with 3, 4, or 5 atoms between the nucleophile and the group X; and wherein X is a good leaving group or a halogen. 12. An antineoplastic compound of claim 10 wherein: X is chlorine; and wherein the nucleophile is a hydroxy group; an amino group; a carboxylate group; or a thiol. 13. An antineoplastic compound of claim 10 wherein the masked nucleophile is an acyloxy group; an acyl-sulfanyl group; or acyl-amino group. 14. An antineoplastic compound of claim 10 which when exposed to a tumor associated protease or esterase is rendered toxic to a cell; wherein the tumor associated protease is selected from the following group consisting of: urokinase; tissue plasminogen activator, Cathepsin B; Cathepsin C; Cathepsin D; plasmin; collagenase; Type IV collagenase; stromelysin; and dipeptidyl peptidase. 15. An antineoplastic compound of claim 1 in which R1 and R2 are --NHCH.sub.2 CH.sub.2 Cl. 16. An antineoplastic compound of claim 1 in which R1 is --N(CH.sub.2 CH.sub.2 Cl.).sub.2 and R2 is --NH.sub.2. 17. An antineoplastic compound of claim 1 of the following structure: ##STR28## 18. A method for killing tumor cells comprising contacting the cells in vitro or in vivo with a concentration of a compound of claim 1 high enough to achieve the desired effect. 19. A method of treating tumors in a patient in need thereof comprising administering an effective amount of a compound of claim 1. 20. A method for killing tumor cells comprising contacting the cells in vitro or in vivo with a concentration of a compound of claim 6 high enough to achieve the desired effect. 21. A method of treating tumors in a patient in need thereof comprising administering an effective amount of a compound of claim 6. 22. A method for killing tumor cells comprising contacting the cells in vitro or in vivo with a concentration of a compound of claim 10 high enough to achieve the desired effect. 23. A method of treating tumors in a patient in need thereof comprising administering an effective amount of a compound or claim 10. 24. A method for killing tumor cells comprising contacting the cells in vitro or in vivo with a concentration of a compound of claim 7 high enough to achieve the desired effect. 25. A method of treating tumors in a patient in need thereof comprising administering an effective amount of a compound of claim 7.

Details for Patent 5,659,061

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2039-02-26
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-02-26